Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EVO
stocks logo

EVO

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
3 Analyst Rating
up Image0
Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 8.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
1 Sell
Moderate Buy
up Image0
Current: 4.260
sliders
Low
3.00
Averages
6.00
High
8.00
up Image0
Current: 4.260
sliders
Low
3.00
Averages
6.00
High
8.00
RBC Capital
Charles Weston
Outperform
maintain
2025-05-15
Reason
RBC Capital
Charles Weston
Price Target
2025-05-15
maintain
Outperform
Reason
RBC Capital analyst Charles Weston raised the firm's price target on Evotec to EUR 11.90 from EUR 11.60 and keeps an Outperform rating on the shares.
Deutsche Bank
Sell -> Hold
upgrade
2025-04-24
Reason
Deutsche Bank
Price Target
2025-04-24
upgrade
Sell -> Hold
Reason
Deutsche Bank upgraded Evotec to Hold from Sell with a price target of EUR 7, up from EUR 4. The company provided new guidance for 2025 and the medium term, "offering much-needed direction," the analyst tells investors in a research note. The firm says the guidance appears achievable. Although the projected adjusted EBITDA level is "disappointing and should lead to significant consensus earnings cuts, it should provide a reasonable floor" for the shares, contends Deutsche Bank.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$8
2024-11-07
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$8
2024-11-07
Reiterates
Strong Buy
Reason
Jefferies
Benjamin Jackson
Strong Buy
to
Hold
Downgrades
$8.7 → $3.8
2024-10-07
Reason
Jefferies
Benjamin Jackson
Price Target
$8.7 → $3.8
2024-10-07
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Maintains
$11 → $8
2024-08-15
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$11 → $8
2024-08-15
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Evotec SE (EVO.O) is -11.57, compared to its 5-year average forward P/E of 466.56. For a more detailed relative valuation and DCF analysis to assess Evotec SE 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
466.56
Current PE
-11.57
Overvalued PE
2559.11
Undervalued PE
-1625.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
37.35
Current EV/EBITDA
25.47
Overvalued EV/EBITDA
58.02
Undervalued EV/EBITDA
16.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
5.22
Current PS
1.46
Overvalued PS
8.41
Undervalued PS
2.02

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

EVO News & Events

Events Timeline

(ET)
2024-11-29
09:42:24
Evotec Chief Operating Officer to step down on December 31
select
2024-11-22 (ET)
2024-11-22
10:02:49
Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy
select
2024-11-22
07:44:25
Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.5
06-25Benzinga
Evotec's Collaboration Sparks Hope For Acute Kidney Injury Breakthroughs

  • Evotec's Stock Surge: Evotec SE shares rose by 3.19% in premarket trading after the company announced its participation in the NURTuRE-AKI consortium, which aims to develop a comprehensive patient database for acute kidney injury (AKI) research and therapeutic discovery.

  • NURTuRE-AKI Initiative: The initiative will collect extensive biological and medical data from vulnerable AKI patients, enhancing Evotec's E.MPD platform for precision medicine and potentially accelerating breakthroughs in kidney care through the identification of molecular targets and biomarkers.

Preview
2.0
05-28Benzinga
DHT Holdings Posts Weak Sales, Joins Compass Diversified, Okta And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

  • U.S. Stock Market Overview: U.S. stock futures are down, with the Dow futures falling about 0.2%. DHT Holdings saw a significant drop in pre-market trading after reporting quarterly sales that missed expectations, despite earnings beating estimates.

  • Other Stocks Performance: Several companies experienced declines in pre-market trading, including Compass Diversified (-13.5%) due to financial irregularities, Okta (-12.8%) amid economic uncertainty, and Galaxy Digital (-8.5%) following a public offering announcement.

Preview
9.5
05-06NASDAQ.COM
Evotec Net Loss Widens In Q1; Confirms FY25, FY28 Revenue Guidance

  • Financial Performance: Evotec SE reported a wider net loss of 31.58 million euros in Q1, with revenues declining by 4% to 199.98 million euros, primarily due to lower earnings in the Shared R&D segment.

  • Future Outlook: The company anticipates group revenues for 2025 to be between 840 million and 880 million euros, with expected adjusted EBITDA reaching 30 to 50 million euros, while projecting an annual growth rate of 8% to 12% for revenues from 2024 to 2028.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Evotec SE (EVO) stock price today?

The current price of EVO is 4.26 USD — it has increased 0.47 % in the last trading day.

arrow icon

What is Evotec SE (EVO)'s business?

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

arrow icon

What is the price predicton of EVO Stock?

Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Evotec SE (EVO)'s revenue for the last quarter?

Evotec SE revenue for the last quarter amounts to 210.25M USD, decreased -7.23 % YoY.

arrow icon

What is Evotec SE (EVO)'s earnings per share (EPS) for the last quarter?

Evotec SE. EPS for the last quarter amounts to -0.19 USD, increased 46.15 % YoY.

arrow icon

What changes have occurred in the market's expectations for Evotec SE (EVO)'s fundamentals?

The market is revising Downward the revenue expectations for Evotec SE (EVO) for FY2025, with the revenue forecasts being adjusted by -2.43% over the past three months. During the same period, the stock price has changed by 18.99%.
arrow icon

How many employees does Evotec SE (EVO). have?

Evotec SE (EVO) has 4827 emplpoyees as of July 19 2025.

arrow icon

What is Evotec SE (EVO) market cap?

Today EVO has the market capitalization of 1.51B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free